iRhythm Holdings, Inc.
No enriched coverage for $IRTC in the last 7 days.
iRhythm (IRTC) reported Q2 2026 revenue of $224.2M, up 20.1% YoY, with gross margin at 72.8%. GAAP net loss was $0.4M, and adjusted EBITDA was $43.3M. Full-year revenue guidance is $880M to $890M and adjusted EBITDA margin 13% to 14%. The company agreed to acquire VitalConnect for about $287.5M and received a $50M Baxter settlement.
iRhythm Holdings, Inc. (IRTC) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. irtc-20260811 0001388658 false 0001388658 2026-08-11 2026-08-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported):
Blackford Quentin S. (President and CEO) sold 26,859 shares of iRhythm Holdings, Inc. (IRTC) at $124.65 ($3.35M total) on 2026-08-10.
Recent IRTC coverage spans insider activity, mergers & acquisitions and earnings.
In the last 30 days, IRTC insiders filed 8 SEC Form 4 transactions — no purchases and 8 sales ($7.3M). The most active reporter was Patterson Chad, CHIEF COMM & PRODUCT OFFICER, with 2 filings.
The call combines earnings/guidance with a sizable acquisition and litigation resolution, shifting near-term valuation and execution risk.
Board/Audit Committee leadership change is a governance update that can affect perceived oversight quality, but the filing provides no operational or financial guidance.
This is an insider sale disclosure, not a company fundamental update, but it can affect near-term sentiment and positioning.
This is a routine insider open-market sale with no 10b5-1 plan stated, but it does not by itself signal a fundamental change.
This is an insider open-market sale with no 10b5-1 plan stated, which can modestly affect sentiment but is not a fundamental update.
alphai scores every news story that mentions IRTC with an AI model for sentiment and relevance, and aggregates insider trades from iRhythm Holdings, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
iRhythm (IRTC) reported Q2 2026 revenue of $224.2M, up 20.1% YoY, with gross margin at 72.8%. GAAP net loss was $0.4M, and adjusted EBITDA was $43.3M. Full-year revenue guidance is $880M to $890M and adjusted EBITDA margin 13% to 14%. The company agreed to acquire VitalConnect for about $287.5M and received a $50M Baxter settlement.
6 min readiRhythm Holdings, Inc. (IRTC) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. irtc-20260811 0001388658 false 0001388658 2026-08-11 2026-08-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported):
2 min readBlackford Quentin S. (President and CEO) sold 26,859 shares of iRhythm Holdings, Inc. (IRTC) at $124.65 ($3.35M total) on 2026-08-10.
1 min readMurphy Patrick Michael (CBO and CLO) sold 7,093 shares of iRhythm Holdings, Inc. (IRTC) at $124.65 ($0.88M total) on 2026-08-10.
1 min readPatterson Chad (CHIEF COMM & PRODUCT OFFICER) sold 7,093 shares of iRhythm Holdings, Inc. (IRTC) at $124.65 ($0.88M total) on 2026-08-10.
2 min readShrishrimal Sumi (EVP, Chief Risk Officer) sold 5,372 shares of iRhythm Holdings, Inc. (IRTC) at $124.65 ($0.67M total) on 2026-08-10.
1 min readTurakhia Minang (CHIEF MED/SCI OFCR EVP ADVTECH) sold 7,093 shares of iRhythm Holdings, Inc. (IRTC) at $124.65 ($0.88M total) on 2026-08-10.
1 min readiRhythm Holdings agreed to acquire private wearable biosensor firm VitalConnect for about $287.5M. The deal includes $237.5M cash from iRhythm’s balance sheet and $50M in iRhythm common stock, plus up to $30M interim working capital financing. iRhythm expects revenue growth contribution in 2027 and 15% adjusted EBITDA margin, with closing by end-2026.
3 min readiRhythm Holdings agreed to acquire VitalConnect for about $287.5M. The deal includes $237.5M cash from iRhythm’s balance sheet and $50M in iRhythm common stock, plus up to $30M interim working capital financing before closing. iRhythm expects closing by end-2026 and projects revenue growth accretion in 2027 while keeping a 15% adjusted EBITDA margin.
3 min readiRhythm Technologies (IRTC) shares fell about 2.8% after Truist cut its price target to $18 from $160, keeping a Buy rating. The move followed iRhythm’s strong Q2 results, including $224.2M revenue (+20.1% YoY) and EPS of $0.58, and a raised FY revenue guidance midpoint to $885M.
4 min read
